The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

PARP inhibitors (PARPi) have changed the management of patients with ovarian cancer and their effectiveness has been demonstrated especially in homologous recombination repair–deficient tumors. These first-generation drugs target PARP1, but also PARP2 and other family members potentially responsible...

Descripción completa

Detalles Bibliográficos
Autores principales: Dellavedova, Giulia, Decio, Alessandra, Formenti, Laura, Albertella, Mark R., Wilson, Joanne, Staniszewska, Anna D., Leo, Elisabetta, Giavazzi, Raffaella, Ghilardi, Carmen, Bani, Maria Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042207/
https://www.ncbi.nlm.nih.gov/pubmed/36994441
http://dx.doi.org/10.1158/2767-9764.CRC-22-0423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042207/
https://www.ncbi.nlm.nih.gov/pubmed/36994441
http://dx.doi.org/10.1158/2767-9764.CRC-22-0423

Ejemplares similares